461 related articles for article (PubMed ID: 1102191)
1. Patho-anatomical features of the bone marrow.
Lennert K; Nagai K; Schwarze EW
Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
[No Abstract] [Full Text] [Related]
2. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
3. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
4. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
6. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of polycythemia vera based on bone marrow pathology.
Thiele JM; Kvasnicka HM
Curr Hematol Rep; 2005 May; 4(3):218-23. PubMed ID: 15865875
[TBL] [Abstract][Full Text] [Related]
8. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
9. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
10. [Clinical course and transformation of polycythemia vera and its relation to applied therapy].
Burger T; Schmelczer M; Molnár L; Pajor L; Koszorús S
Orv Hetil; 1987 Dec; 128(52):2723-30. PubMed ID: 3431872
[No Abstract] [Full Text] [Related]
11. [Acute myelofibrosis--case reports of acute megakaryoblastic leukemia and acute myeloblastic leukemia].
Ishibashi T; Uchida T; Matsuda S; Sato T; Kimura H; Shichishima T; Mita M; Suzuki A; Kariyone S
Rinsho Ketsueki; 1985 Jul; 26(7):1145-50. PubMed ID: 3863978
[No Abstract] [Full Text] [Related]
12. Definition, clinical features and diagnosis of polycythaemia vera.
Gilbert HS
Clin Haematol; 1975 Jun; 4(2):263-90. PubMed ID: 1102188
[No Abstract] [Full Text] [Related]
13. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
14. [Thrombocythaemia - is there a primary form? ((author's transl)].
Hartwich G; Schirmbeck H; Mörl M
Med Klin; 1975 Dec; 70(49):2005-8. PubMed ID: 1060913
[TBL] [Abstract][Full Text] [Related]
15. The bone marrow in myeloproliferative and dysmyelopoietic syndromes.
Wolf BC; Neiman RS
Hematol Oncol Clin North Am; 1988 Dec; 2(4):669-94. PubMed ID: 3065324
[TBL] [Abstract][Full Text] [Related]
16. Primary polycythaemia. 3. Studies on the significance of the history of the disease and of the treatment for the development of clones in bone marrow cells.
Visfeldt J; Franzén S; Nielsen A; Tribukait B
Acta Pathol Microbiol Scand A; 1973 Mar; 81(2):195-203. PubMed ID: 4734062
[No Abstract] [Full Text] [Related]
17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
18. Abnormal myelopoietic clones in man.
McCulloch EA
J Natl Cancer Inst; 1979 Oct; 63(4):883-92. PubMed ID: 384008
[No Abstract] [Full Text] [Related]
19. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
20. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
